If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]
Conference call and webcast: Tuesday, September 13, 2022 at 2:30 p.m. (Paris time)
▪ Sale of the cell therapy production plant in the United States to Catalent in April 2022
▪ Ongoing evaluation of partnership opportunities, strategy planned for Q4 2022
▪ Cessation of activities in view of submitting an application for approval of Graspa® in the treatment of patients with Acute Lymphoblastic Leukemia (ALL)
▪ Cash and cash equivalents amounting to €53.3 million ($55.8 million) at the end of June 2022